Transforming Growth Factor Beta Signaling in Growth of Estrogen-Insensitive Metastatic Bone Lesions
Annual summary 15 Dec 2008-14 Dec 2011
INDIANA UNIV INDIANAPOLIS
Pagination or Media Count:
While many women with breast cancer will use estrogen receptor therapeutics such as fulvestrant, resistance is nearly inevitable. Recently, it has been noted that the epidermal growth factor receptor EGFR family plays a vital role in metastasis to bone also cross signaling with the transforming growth factor receptor type II TGFBR2 has been noted to increase levels of destructive environmental cytokines. Therefore we are examining the role of EGFRTGFBR2 cross talk in bone metastatic breast cancer. The study of these pathways are important to metastatic breast cancer, as they have been known to increase levels of the destructive cytokine parathyroid hormone related protein PTHrP, which causes increased osteolysis within the bone environment. To elucidate the connection between these two vital receptors may led to further progression in therapeutics for those women with EGFR positive tumors.
- Medicine and Medical Research